Panel Discussion: What’s Next for DDR Therapeutics? Evaluating Next-Gen PARP Inhibitors, Novel Targets, & the Future of Clinical Validation
Time: 4:15 pm
day: Day Two
Details:
- How are biopharma validating novel DDR targets, and what role will next-gen PARP inhibitors play in the evolving landscape of DDR therapeutics?
- What preclinical frameworks are currently in use for DDR inhibitors, and how can they be enhanced to better predict clinical success and viability?
- As we look to the future, could expanding data access—such as sharing DDRi trial results and patient genome sequencing—help create a more patient-centric approach to clinical trials for DDRi-sensitive cancers?
